These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16639340)

  • 1. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
    Ramachandran G; Hemanthkumar AK; Rajasekaran S; Padmapriyadarsini C; Narendran G; Sukumar B; Sathishnarayan S; Raja K; Kumaraswami V; Swaminathan S
    J Acquir Immune Defic Syndr; 2006 May; 42(1):36-41. PubMed ID: 16639340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
    Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
    Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
    Ribera E; Pou L; Lopez RM; Crespo M; Falco V; Ocaña I; Ruiz I; Pahissa A
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):450-3. PubMed ID: 11744833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
    Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K
    Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
    Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
    Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
    Oudijk JM; McIlleron H; Mulenga V; Chintu C; Merry C; Walker AS; Cook A; Gibb DM; Burger DM
    AIDS; 2012 Jul; 26(12):1523-8. PubMed ID: 22546991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
    Matteelli A; Saleri N; Villani P; Bonkoungou V; Carvalho AC; Kouanda S; Sanou MJ; Simporé J; Monno L; Carosi G; Regazzi M; Dembele M
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):64-9. PubMed ID: 19731452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
    Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
    Lamorde M; Byakika-Kibwika P; Okaba-Kayom V; Ryan M; Coakley P; Boffito M; Namakula R; Kalemeera F; Colebunders R; Back D; Khoo S; Merry C
    J Antimicrob Chemother; 2011 Jan; 66(1):180-3. PubMed ID: 21047828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
    Maartens G; Decloedt E; Cohen K
    Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
    Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tuberculosis therapy on nevirapine trough plasma concentrations.
    Dean GL; Back DJ; de Ruiter A
    AIDS; 1999 Dec; 13(17):2489-90. PubMed ID: 10597799
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.